Once-daily glycopyrronium via the Breezhaler® device for the treatment of COPD: pharmacological and clinical profile.
Molimard, Mathieu
Once-daily glycopyrronium via the Breezhaler® device for the treatment of COPD: pharmacological and clinical profile. [electronic resource] - Expert review of clinical pharmacology Sep 2013 - 503-17 p. digital
Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Review
1751-2441
10.1586/17512433.2013.828419 doi
Administration, Inhalation
Animals
Clinical Trials as Topic
Drug Administration Schedule
Dry Powder Inhalers
Glycopyrrolate--administration & dosage
Humans
Molecular Structure
Muscarinic Antagonists--administration & dosage
Pulmonary Disease, Chronic Obstructive--drug therapy
Treatment Outcome
Once-daily glycopyrronium via the Breezhaler® device for the treatment of COPD: pharmacological and clinical profile. [electronic resource] - Expert review of clinical pharmacology Sep 2013 - 503-17 p. digital
Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Review
1751-2441
10.1586/17512433.2013.828419 doi
Administration, Inhalation
Animals
Clinical Trials as Topic
Drug Administration Schedule
Dry Powder Inhalers
Glycopyrrolate--administration & dosage
Humans
Molecular Structure
Muscarinic Antagonists--administration & dosage
Pulmonary Disease, Chronic Obstructive--drug therapy
Treatment Outcome